KR20120067683A - Plant origin lactic acid bacteria lactobacillus plantarum dsr j1-8 having preventing effect of metabolic syndrome and its use - Google Patents

Abstract

PURPOSE: A Lactobacillus plantarum DSR J1-8(deposit number: KCCM11141P) for preventing and treating metabolic syndrome is provided to suppress alpha-glucosidase activity and to enhance acid and salt tolerance, thermal resistance, and antibiotics resistance. CONSTITUTION: A Lactobacillus plantarum DSR J1-8(deposit number: KCCM11141P) has an activity of suppressing alpha-glucosidase and alpha-amylase. A pharmaceutical composition for preventing and treating metabolic syndrome contains the strain or culture thereof. A probiotic composition contains the strain or culture thereof. A feed composition contains the strain or culture thereof. A food additive composition contains the strain or culture thereof.

Description

Plant lactic acid bacteria Lactobacillus plantarum DSR J1-8 having preventing effect of metabolic syndrome and its use}

The present invention relates to lactic acid bacteria and its use, which are effective in the prevention and treatment of metabolic syndrome, more specifically, acid resistance, flame resistance, bile resistance, antibiotic resistance, heat safety, α-glucosidase inhibitory activity and α-amylase The present invention relates to a Lactobacillus plantarium DSR J1-8, a strain having an activity inhibitory activity, and a use thereof.

According to a recent survey by the Epidemiological Subcommittee of the Korean Diabetes Association and the Korea Health Insurance Review and Assessment Service, as of 2003, the number of diabetic patients in Korea was 4.29 million, or 8.29% of the total population. It is estimated that 6.2 million people will be diagnosed by 2020 and 7.2 million by 2030. At that time, it is feared that one person for every seven people in Korea will have diabetes.

Diabetes is a chronic disease that is one of the leading causes of death in Korea, and the mortality rate from diabetes is increasing rapidly from 4.3 in 100,000 in 1983 to 13.1 in 1995, and is estimated to be 15.9 in 2005. Therefore, prevention and management of diabetes and prevention of complications are very important.

Diabetes is even more fearful because it causes complications that cause other illnesses as well as illness itself, and once it develops, its cure is difficult, and prevention is best. Once confirmed, diabetes is treated continuously. There is a difficulty to receive.

Therefore, there is an urgent need for the development of drugs or foods having no side effects for the prevention and / or treatment of diabetes. Until now, much research has been focused on the development of a single substance having antidiabetic effect from a natural material that suppresses the rise of blood sugar. However, many studies and commercial foods still do not produce satisfactory results on the effects of diabetes suppression.

In vivo digestion of ingested food usually results in the breakdown of some proteins in the stomach, including the initial breakdown of carbohydrates in the oral cavity. However, full-scale carbohydrate and fat digestion and absorption occurs mainly in the area from the duodenum to the ileum, and in general, it is known that resorption of water and salts and absorption of free fatty acids occur mainly in the large intestine. Therefore, the most important part of digestive absorption occurs in the small intestine.Proteolytic enzymes such as trypsinogen, chymotrypsinogen, and carboxy peptidase secreted by the pancreas, lipolytic enzymes such as pancreatic lipase, and stepin, pancreatic amylase, amylose and maltase Mass ingested by various digestive enzymes such as carbohydrate degrading enzymes and various peptidase, nucleic acid degrading enzymes, alginase, phosphatase, and various glycolytic enzymes, lactose degrading enzymes in small intestine As a result, the nutrients absorbed through the ducts and blood vessels are moved into the body. Therefore, inhibiting amylase activity, which plays an important role in intestinal digestion, prevents carbohydrates from being broken down into low-saccharide substances that are absorbed into the body, thereby inhibiting excessive carbohydrate absorption.

Carbohydrates in food are broken down into monosaccharides such as glucose by the action of various alpha-glucosidases such as alpha-amylase, isomaltase, glucoamylase, and sucrase. Is absorbed. Therefore, inhibiting the action of these alpha-glucosidase, carbohydrates are not broken down into monosaccharides, so they are not absorbed into the blood. Therefore, a sudden rise in the glucose concentration in the blood caused by carbohydrate intake is suppressed.

Therefore, many studies have been made on inhibitors of the action of alpha-glucosidase enzymes essential for carbohydrate metabolism for the purpose of controlling blood glucose lowering. As a result, oligostatin (oligostatin, Itoh, J. et al. J.Antibiotics, 1981, 34. 1424), trestatin (trestatin, Yokose, K. et al. J. Antibiotics, 1983, 36. 1157) obtained from the culture of soil actinomycetes. In 1977, Bayer, Germany, discovered acarbose (acarbose, Schmidt, DD, etc., Naturwis senschaften, 1977, 64.535) and developed it to treat diabetes and obesity. In addition, we are currently conducting clinical trials on valoliolamine in pharmaceuticals in Japan and miglitol, a deoxynojirimycin derivative in Bayer, Germany (Foelsch, UR et al., Structrue and Function of the small intestine; Caspyry, WF ed.p310-318.Excerptamedica, Amsterdam, 1987).

To date, many types of diabetes treatments have been developed and development is underway, but no satisfactory treatment method or drug has been developed. In the conventional treatment method, insulin is directly administered to insulin-dependent patients or sulfonylurea derivatives are administered to insulin-independent patients to control the concentration of glucose in the blood. However, insulin can cause side effects such as allergic reactions, and since it is destroyed in the digestive tract before reaching the blood flow, it cannot be administered orally, so it is used only as an injection, so it is repeated injection in patients who need regular injection for a long time. It has a problem causing edema of the skin. In addition, sulfonyl urea-based drugs such as tolbutamide and gliquidone may cause hypoglycemia when used in combination with chloramphenicol, β-blockers, and sulfa agents, and biguanides such as metformin. (biguanide) -based drugs have problems that cause excessive lactic acid when used in combination with alcohol.

In recent years, diabetes has been increasing rapidly. The government has decided to use diabetes as a special management disease and promote diabetes management at the national level. However, most of the functional foods for diabetics are low-calorie foods, and functional ingredients that help direct blood sugar control in Korea. Absent

Therefore, for diabetic patients who need blood sugar management, there is no restriction on the intake of nutrients, and it is suitable for diabetic patients who can inhibit the absorption of carbohydrates without inhibiting the absorption of essential ions and proteins other than the diet used for conventional diabetes. Development of the method is required. In order to overcome the problems of the conventional method of controlling the glucose concentration in the blood, a new method for preventing the absorption of glucose itself in the blood has been attempted. One of the new methods has been to develop alpha-glucosidase inhibitors as a diabetes treatment.

Diabetes, on the other hand, is a condition in which a large amount of glucose is excreted in the urine, causing many complications such as cataracts, skin ulcers, multiple-prone purulents, neuralgia and renal failure, affecting fat metabolism or causing disorders such as acidosis) can cause serious complications such as falling into diabetic coma. Diabetes is largely classified into two types: Insulin Dependent Diabetes Mellitus (IDDM) and Non-Insulin Dependent Diabetes Mellitus (NIDDM). It is known to account for more than% (Park Kyung-soo. J. Ginseng Res., 2003, 56-61). As a method for preventing and treating type 2 diabetes, 1) dietary control, 2) exercise therapy, 3) oral hypoglycemic agents, and 4) insulin preparations are used. Among them, insulin secretion is used as a representative drug of oral hypoglycemic agents. Sulfonin urea promoting agent, metformin improving insulin resistance, glycazone family, and alpha-glycosidase inhibitor inhibiting glucose absorption. However, these oral hypoglycemic agents are limited in use due to side effects such as liver toxicity, weight gain, hypoglycemia and the like.

In modern people, obesity is becoming a threat to national health as the amount of exercise decreases and the diet is changed from eating vegetarian to eating more fat and calories than necessary. Obese people are reported to be shorter than normal people because of high incidence and risk of surgery such as diabetes, arteriosclerosis, hypertension, heart disease, liver disease, gallstones, gout and kidney disease. Conjugated linoleic acid (patent publication 10-2007-0096995) and conjugated linolenic acid composition containing Lactobacillus reuteri as a composition for the purpose of reducing body fat for the treatment of obesity 10-2001-0047292), a composition containing red ginseng saponin and uiyiin (Patent Publication 10-2006-0002087), and Cheonggukjang made by culturing mushroom mycelium in soybean (Publication Patent Publication 10-2006-0021011) and the like.

Early obesity treatments include calorie therapy that increases the use of calories, diets that reduce the absorption of calories, and behavioral therapy. Recently, drug treatments such as digestive enzyme inhibitors, appetite suppressants, and lipolytic agents are commonly used. It is often used. There are two types of drugs that are approved for long-term use: sibutramine and orlistat. Sibutramine is a form of appetite suppressant that, on average, reduces body weight by about 5% to 9%. However, you may need to check your blood pressure and pulse rate periodically because you may experience side effects such as headaches, cravings (severe thirst), insomnia, and constipation. Orlistat is a drug that inhibits fat digestion in the body by inhibiting lipolytic enzymes. About 30% of the ingested fat is not digested and absorbed, but it is discharged out of the body as it is, but as a side effect, stool may be frequently dried up or fatty stool may appear. have.

Recently, interest in the use of various food materials whose safety and efficacy have been proven for a long time as well as appropriate exercise as a method for preventing and treating adult diseases such as obesity. Currently, foods containing dietary fiber, herbal medicines and various food ingredients have been developed as health foods for obese people, but their effects are insignificant, and their normal life is difficult due to side effects due to lack of various nutrients. If you stop taking it, you will quickly become obese again.

Therefore, considering the dietary patterns of Koreans with the highest intakes of carbohydrates, diet products whose main mechanisms are the existing mechanisms that limit the intake of total nutrients, the intestinal cleaning effect using dietary fiber, and the inhibition of digestion of fat Since it is not suitable, there is a need to develop a differentiated method suitable for Koreans who can inhibit the absorption of carbohydrates without inhibiting the absorption of other essential inorganic ions and proteins.

As microorganisms having a very beneficial effect on human health, their usefulness is increasing day by day. In recent years, research on lactic acid bacteria has been actively conducted, as well as general foods, as well as being developed as a health food and medicine, the application range is getting wider. The microorganisms belonging to the lactic acid bacteria include Streptococcus, Pediococcus, Leukonostoc, Lactobacillus, Sporactobacillus, and Bifidobacterium. Microorganisms of the genus Bifidobacterium).

These lactic acid bacteria play an important role in maintaining intestinal health by decomposing nutrients and fiber ingested by animals while using them as energy sources, producing lactic acid and antibiotics, and inhibiting the growth of harmful bacteria in the intestine. In addition, lactic acid bacteria have been used to promote the growth of animals and improve feed utilization, increase resistance to diseases, inhibit the growth of harmful bacteria, reduce mortality, inhibit the production of toxic toxins and produce various vitamins. However, in order for the lactic acid bacteria to exert such efficacy, it must reach the intestine safely, attach to the intestinal mucosa, and display its function. To this end, it should be a strain that can be directly attached to the intestine, and should be able to meet the basic conditions such as less destruction by gastric acid during oral administration, and strong resistance to bile acids.

On the other hand, it has been reported that the effect of lactic acid bacteria on diabetes, if oral administration of Lactobacillus casei ( Lactobacillus casei ) to the type 1 diabetes in mice with alloxan (alloxan) only lowers the incidence of diabetes Rather, blood glucose levels have been reported (Matsuzaki T et al., 1997. APMIS. 637-642). In addition, administration of Lactobacillus casei to KK-Ay mice, transgenic animals of type 2, resulted in hypoglycemic and weight gain inhibition, and changes in cytokines such as IFN-γ and IL-2 and plasma insulin levels. Decrease was found (Matsuzaki T et al., Endocrine J., 1997, 44, 357-365). Yadav et al. Also found that rats fed a high-calorie diet ingested dahi containing Lactobacillus ashophilus and Lactobacillus casei, blood glucose, plasma insulin, glucose tolerance, triglycerides, LDL, and blood It has been reported that the level of free fatty acids can be greatly reduced to lower the incidence of diabetes (Yadav H et al., Nutrition, 2007, 23, 62-68).

The present invention relates to a composition for regulating obesity and blood glucose using lactic acid bacteria having excellent α-glucosidase inhibitory activity and having an ability to inhibit α-amylase activity, and specifically, to develop lactic acid bacteria having inhibitory activity against alpha amylase and alpha glucosidase. The present invention relates to a composition for controlling blood sugar of obese people and a glycemic control composition for inhibiting blood glucose increase in diabetic patients by inhibiting amylase and glucosidase activity of intestinal carbohydrate degrading enzymes. The present invention is a microorganism having a blood glucose increase inhibitory effect and an obesity function improving effect, a microbial agent containing the microorganism, a method for producing a microbial agent containing the microorganism, a food containing the microorganism, the production of a food containing the microorganism To provide a method.

The present invention can greatly improve the quality of life of obese and diabetic as a functional raw material that can be used for controlling blood sugar and preventing and treating obesity by inhibiting the final absorption of carbohydrates in the body.

Therefore, an object of the present invention is a novel lactic acid bacterium having a preventive and therapeutic effect on metabolic syndrome, which is a lactic acid bacterium having excellent acid resistance, flame resistance, antibiosis, antibiotic resistance, heat safety, α-glucosidase inhibitory activity, and α-amylase activity inhibitory activity. Lactobacillus plantarium DSR J1-8 and its metabolic syndrome prevention composition, probiotic composition, feed composition, food additive composition, fermented food is to provide a use

In order to achieve the above object, the present invention is excellent in α-glucosidase inhibitory activity, α-amylase activity inhibitory, antibiotic resistance, acid resistance at pH 2.5 and 3, salt resistance at 10% and 15% NaCl, Oxgal at 0.3% and 0.5% provides bile resistant and heat resistant Lactobacillus plantarium DSR J1-8.

In order to achieve the another object of the present invention, the present invention provides a pharmaceutical composition, probiotic composition, feed composition or food additive composition for preventing and treating metabolic syndrome containing the Lactobacillus plantarium or a culture thereof.

In addition, the present invention provides a fermented food containing the Lactobacillus plantarium or a culture thereof to achieve another object of the present invention.

The present invention also provides a method for producing a fermented food using the Lactobacillus plantarium or its culture as a starter.

Hereinafter, the present invention will be described in detail.

Lactobacillus plantarium of the present invention is excellent in α-glucosidase inhibitory activity and has the ability to inhibit α-amylase activity, and is characterized by having acid resistance, heat resistance, salt resistance, bile resistance and antibiotic resistance. In particular, the Lactobacillus plantarium DSR J1-8 of the present invention isolated from kimchi is excellent in α-glucosidase inhibitory activity of 81.83%, α-amylase inhibitory activity is 10.2%, acid resistance at pH 2.5 and 3, It is characterized by heat resistance at 65 ° C., flame resistance at 10% and 15% NaCl, and 0.3% and 0.5% bile resistance to oxgall (see Examples 1-2 to 1-8).

Lactobacillus plantarium DSR J1-8 of the present invention is a strain whose α-glucosidase inhibitory activity is 8 times or more than that of α-amylase inhibitory activity, inhibits carbohydrate small glycosylation, inhibits blood sugar rise and suppresses appetite. While inhibiting obesity, side effects such as abdominal bloating and diarrhea due to abnormal infermentation of starch ingested starch intestinal inseparated by over-inhibition of α-amylase and resulting in intestinal proteolytic bacteria can be reduced.

In addition, the Lactobacillus plantarium of the present invention survives more than 53.93% at pH 2.5, has strong acid resistance, survives at least 90% in NaCl 15%, has strong flame resistance, and shows a survival rate of 100% or more at 0.5% of oxgall. Has bile resistance

Since the Lactobacillus plantarium of the present invention is excellent in acid resistance, flame resistance, and bile resistance, oral ingestion of the strain is a digestive enzyme secreted from a harsh environment in vivo, that is, an acidic environment in which the pH is lowered to 3 or less, and the gastrointestinal and small intestine. And bile acids can also increase the probability of reaching the intestine is excellent growth.

In addition, since the Lactobacillus plantarium of the present invention is excellent in antibiotic resistance, it is possible to grow even in the presence of antibiotics and thus have a beneficial function in vivo (see Example 1-7).

As described above, the Lactobacillus plantarium strain having excellent α-glucosidase inhibitory activity and an α-amylase activity inhibiting activity, and having both excellent acid and salt resistance, heat resistance, antibiotic resistance, and bile resistance in the present invention It is the first one to be provided.

Therefore, the lactic acid bacterium of the present invention can be used as a pharmaceutical composition, a probiotic composition, a feed composition or a food additive composition for the purpose of promoting health of humans and animals, that is, preventing and treating metabolic syndrome. The composition may include the live bacteria, dried bacteria or culture of the Lactobacillus plantarium of the present invention as an active ingredient, and may further include an excipient or a carrier. The culture includes a culture solution itself cultured in a liquid medium, a filtrate (centrifuged supernatant) from which the strain is removed by filtration or centrifugation of the culture solution. The content of Lactobacillus plantarium in the composition may vary depending on the use and formulation of the composition.

The compositions can be prepared and administered in a variety of formulations and methods. For example, Lactobacillus plantarium or its culture may be mixed with carriers and flavorings commonly used in the pharmaceutical arts for tablets, troches, capsules, elixir ), Syrup, powder, suspension or granules, and the like. As the carrier, a binder, a lubricant, a disintegrant, an excipient, a solubilizer, a dispersant, a stabilizer, a suspending agent and the like can be used. The mode of administration may be oral, parenteral or application, but preferably oral administration. In addition, the dosage may be appropriately selected depending on the absorbency, inactivation rate and excretion rate of the active ingredient in the body, age, sex, condition, etc. of the recipient.

Lactobacillus plantarium or its culture according to the present invention can be used as a food additive for food such as kimchi, beverages, baby food, dairy products. In addition, the Lactobacillus plantarium of the present invention can be used as a starter (starter) for the production of fermented food. The fermented foods include cheese, kimchi, fermented reproductive products and the like. Fermented foods using the Lactobacillus plantarium of the present invention can be prepared according to conventional methods known in the art.

 The Lactobacillus plantarium according to the present invention can be used to prepare kimchi. Preferably, salted cabbage is mixed with common kimchi seasonings such as red pepper powder, garlic, ginger, leek, radish, and sugar, and then kimchi may be prepared by adding a culture of the Lactobacillus plantarium of the present invention. The culture of the Lactobacillus plantarium of the present invention is preferably added at 0.1 to 5% by weight, and most preferably at 1% by weight based on the total weight of kimchi.

The Lactobacillus plantarium according to the present invention can be cultured in large quantities by a conventional method for culturing Lactobacillus sp. As the culture medium, a medium consisting of a carbon source, a nitrogen source, vitamins, and minerals may be used. For example, MRS (Man-Rogosa-Sharp) medium or Chinese cabbage juice medium may be used. The cabbage juice medium can be used after crushing and juice pickled cabbage, sterilized. Cultivation of the microorganism is possible under the culture conditions of the common Lactobacillus microorganisms, for example, can be cultured for 18 hours to 48 hours at 25 ℃ to 37 ℃, more preferably can be cultured at 37 ℃ 20 hours. The culture medium in the culture may be removed and subjected to centrifugation or filtration to recover only concentrated cells, which steps may be carried out by those skilled in the art as needed. The concentrated cells may be frozen or lyophilized according to a conventional method so as not to lose their activity.

As described above, the novel kimchi lactic acid bacterium of the present invention, Lactobacillus plantarium DSR J1-8, has excellent α-glucosidase inhibitory activity and inhibits α-amylase activity, resistance to acid and heat, salt, antibiotic resistance, It is characterized by excellent bile resistance. Therefore, the lactic acid bacteria of the present invention can be used in various preparations for the pharmaceutical composition for preventing metabolic syndrome, probiotic composition, feed composition, food additive composition and fermented food. In particular, Lactobacillus plantarium DSR J1-8 according to the present invention is effective in preventing metabolic syndrome.

The lactic acid bacteria of the present invention inhibit the activity of the carbohydrate digestive enzymes α-glucosidase and α-amylase to inhibit the absorption of low sugars in the body to prevent the rise of blood sugar, and reduce the excessive intake of nutrients, including diabetes or obesity It is effective in the prevention and treatment of metabolic syndrome, and can lead to satiety due to indigestible carbohydrates can have a diet effect.

Therefore, the lactic acid bacterium of the present invention can be used for the prevention and treatment of metabolic syndrome including diabetes or obesity, and in addition to food or food by controlling the digestion of carbohydrates to regulate the blood sugar of the intake and induces satiety Can be used as a dietary supplement for health foods

1 is a graph showing the activity inhibition rate of the top 20 strains of 600 lactic acid bacteria used in the experiment of Example 1, the activity inhibition rate of α-glucosidase was high.

Hereinafter, the present invention will be described in detail by way of examples.

However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.

≪ Example 1 >

<1-1> Isolation of Lactic Acid Bacteria from Kimchi

30 kinds of kimchi prepared by the conventional kimchi production method were selected, and the kimchi was used as lactic acid bacteria isolated kimchi sample. The kimchi sample was diluted 10-fold with 0.85% saline, and 0.1 ml each of MRS agar medium (MRS agar, Difco .; 10 g of Bakto peptone, 10 g of beef extract, 5 g of yeast extract, 20 g of glucose, twin 801 g, citric acid 2 g, dibasic potassium phosphate 2 g, sodium acetate 5 g, manganese sulfate 0.1 g, magnesium sulfate 0.05 g, agar 15 g / distilled water 1 L) plate was inoculated and plated with a glass rod. The plates were then incubated for 2 days in a 25 ° C. incubator. Each resulting colony was inoculated into MRS agar plates and incubated at 25 ° C. for 2 days to separate a total of 600 lactic acid bacteria colonies.

<1-2> Isolation of Lactic Acid Bacteria with Excellent α-glucosidase Inhibitory Activity

Among the 600 lactic acid bacteria isolated in Example <1-1>, the following experiment was performed to select lactic acid bacteria having excellent α-glucosidase inhibitory activity.

In this experimental example, alpha glucosidase is the first enzyme in carbohydrate digestion process and is a regulator of carbohydrate degradation rate. In order to observe the inhibitory effect of alpha glucosidase of the lactic acid bacteria culture medium, the following experiment was performed.

The lactic acid bacteria were measured for α-glucosidase inhibitory activity using the culture supernatant by centrifugation at 12,000 rpm after incubating for 24 hours at 37 ° C. in MRS medium.

α-glucosidase inhibitory activity was measured by modifying the Dahlqvist method (Assay of intestinal disaccharide. Enzymol. Biol. Clin. (1970). Specifically, 0.05 ml of 0.1 M phosphate buffer (pH 7.2) and α-glucose 0.05 ml of a sidase solution (2 units / ml) and 200 µl of the candidate strain culture were mixed and pre-reacted for 5 minutes at 37 ° C. 100 µl of 2mM PNPG solution, a substrate material, was added and reacted at 37 ° C. for 30 minutes, followed by 1M. Na2CO3 solution After the reaction was stopped by adding 100 µl, the amount of α-nitrophenol produced was measured by absorbance at 405 nm. The control group measured the activity of α-glucosidase using phosphate buffer without adding candidate strain culture or supernatant, and calculated the relative inhibition rate thereof as a control. The absorbance was measured and the inhibition rate was measured to show the top 20 strains (FIG. 1). The lactic acid bacterium exhibited the highest α-glucosidase inhibitory activity as the DSR J1-8 strain.

<1-3> Isolation of Lactic Acid Bacteria with α-amylaes Inhibitory Activity

The following experiment was performed to select lactic acid bacteria having low α-amylase inhibitory activity among the 600 lactic acid bacteria isolated in Example <1-1>.

The lactic acid bacteria were measured for α-amylase inhibitory activity using the culture supernatant by centrifugation at 12,000 rpm after incubating for 24 hours at 37 ° C. in MRS medium.

100 μl of lactic acid bacteria supernatant and 800 μl of potassium phosphate buffer (pH6.8) were added, and 100 μl potato starch (difco) 1ml was added thereto, followed by reaction for 15 minutes in a 37 ° C. water bath. 2 ml of DNS reagent (3,5-dinitro-salicylic acid 10mg / ml, sodium potassium tartarate.4 H20 3g / ml) was added to terminate the reaction and then heated in boiling water for 5 minutes to develop DNS (miller, 1959). ). After cooling to room temperature, 10 ml of distilled water was added to measure absorbance at 540 nm. DNS reagent was used as a blank without enzyme reaction at 37 ° C., and 100 μl of distilled water was used as a control instead of the culture supernatant.

The top 20 strains were indicated by measuring the alpha amylase inhibition rate (Table 1).

Isolate Inhibitory activity (%) Isolate Inhibitory activity (%) DSR J1-1 38.11 DSR J1-11 15.03 DSR J1-2 26.25 DSR J1-12 31.23 DSR J1-3 31.12 DSR J1-13 31.98 DSR J1-4 16.33 DSR J1-14 32.12 DSR J1-5 11.21 DSR J1-15 12.76 DSR J1-6 28.92 DSR J1-16 30.25 DSR J1-7 14.75 DSR J1-17 9.88 DSR J1-8 10.2 DSR J1-18 33.18 DSR J1-9 17.39 DSR J1-19 20.65 DSR J1-10 24.85 DSR J1-20 19.37

In the case of the use of alpha-glucosidase inhibitors for the control of blood glucose, the intestinal influx of starch which was not degraded by excessive inhibition of α-amylase and the abnormal fermentation of starch-degrading bacteria in the colon caused by this Side effects such as bloating and diarrhea have been reported.

Therefore, in the present invention, DSR J1-8 strain having high α-glycosidase inhibitory activity was finally selected among four lactic acid strains with the lowest α-amylase inhibitory activity.

<1-4> Identification of Selected Lactic Acid Bacteria

a. Analysis according to Burgess's classification bacteriology manual

After lactic acid bacteria selected in Examples <1-1,2> were separated into single colonies, morphological and biochemical properties were investigated according to Burges' manual of systematic bacteriology, and gram staining was performed. It was. As a result, it was confirmed that the isolated strain is a Gram-positive strain and has a form of bacilli (Table 2).

characteristic Lactobacillus plantarum DSR J1-8 Gram + Colony form Rod Colony color Yellow Motility - Catalase - Fermentation form Homo Spore - Growth at 15 ℃ + Growth in NaCl 4% +

b. Analysis using API system

Thereafter, the strain was identified by an API system (La Balme-les-Grottes, France). First, bacteria colonies were taken with sterile platinum and then suspended in 2 ml of sterile distilled water. Again, the bacteria solution was suspended in 5 ml of sterile distilled water at a concentration of McFalland Standard Solution No. 2 (MccFaland Standard Solution No. 2) provided by the API 50CH kit (BioMerieux, France). The suspension was added to the liquid medium of the API 50CH kit for homogenization, and then 200 μl of each 50 tubes of the API 50CH kit was inoculated. After spilling on the tube with mineral oil, it was incubated for 48 hours at 30 ℃. The culture was analyzed by the API system to confirm 49 carbohydrate fermentation patterns, and the results were identified by inputting the ATB identification computer system.

As a result, the DSR J1-8 lactic acid bacteria selected in Example <1-2> were found to be a strain belonging to the genus Lactobacillus having a carbohydrate fermentation pattern of Table 3 below.

Control group - D-Mannose + Salinity + Genthio Bios + Glycerol - L-Solvods - Cello beads + D-turanose _ Erythritol - Rhamnose + Maltose + D-Resoz - D-arabinose - Dulcitol - Lactose + D-tagatose - L-arabinose + Inositol - Melibiose + D-fucose - Riboose + Mannitol + Saccharose + L-fucose - D-Xylose - Sorbitol + Trehalose + D-Arabitol - L-Xylose - D-mannoside - Inulin + L-Arabitol - Adonitol - D-glucoside - Melegitos + Gluconate + Xyloxide - Glucosamine + D-Raffinose + 2-ceto-gluconate - Galactose + Amigdalin + Amidodon - 5-ceto-gluconate - D-glucose + Arbutin + Glycogen - D-Fructose + Esculin + Xylitol +

c. 16S rDNA  Sequencing

The nucleotide sequence of 16S rDNA of the selected lactic acid bacteria was analyzed according to a conventional method known in the art. As a result, the 16S rDNA base sequence (SEQ ID NO: 1) of the DSR J1-8 lactic acid bacteria was found to be 99% identical to the 16S rDNA base sequence of the Lactobacillus plantarium.

Accordingly, the inventors named DSR J1-8 lactic acid bacteria as "Lactobacillus plantarium DSR J1-8" and deposited it on December 10, 2010 at the Korean Culture Center of Microorganisms. KCCM11141P].

<1-4> Acid Resistance Test

MRS broth adjusted to pH 2.5, 3.0 with Lactobacillus plantarium DSR J1-8 strain that best inhibits the alpha amylase and alpha glosidase selected in Example <1-2,3> MRS broth, Difco .; 10 g of Bakto peptone, 10 g of beef extract, 5 g of yeast extract, 20 g of glucose, tween 801 g, 2 g of citric acid, 2 g of potassium diphosphate, 5 g of sodium acetate, 0.1 g of manganese sulfate, 10 ml of magnesium sulfate 0.05 g / distilled water 1 l) was inoculated respectively. Thereafter, the number of viable cells was examined while incubating at 37 ° C. for 2 hours.

% Survival / pH pH 2.5 pH 3.0 Lactobacillus plantarum DSR J1-8 53.93 65.27 Lactobacillus plantarum KCTC3108 31.71 42.05

As a result, as shown in Table 4, Lactobacillus plantarium DSR J1-8 is actively growing at pH 2.5 and 3.0, especially 53.93% or more survives at pH 2.5, survival rate of about 65.27% or more at pH 3 It was shown that the acid resistance is strong.

<1-5> flame resistance test

Lactobacillus plantarium DSR J1-8 strain selected in Example <1-2> was inoculated into 10 ml of MRS broth adjusted to 10 and 15% with sodium chloride (NaCl), respectively. Then, the growth of the strain was observed at the salt concentration while incubating for 2 hours at 37 ℃.

Survival Rate (%) / NaCl (%) 10% 15% Lactobacillus plantarum DSR J1-8 100 90 Lactobacillus plantarum KCTC3108 85 68

As a result, as shown in Table 5, the Lactobacillus plantarium DSR J1-8 lactic acid bacteria were active at 10 and 15% sodium chloride, and especially 90% at 15% sodium chloride.

<1-6> bile resistance test

Lactobacillus plantarium DSR J1-8 selected in Example <1-2> was inoculated into 10 ml of MRS broth adjusted to 0.3 and 0.5% with oxgall, respectively. Thereafter, the growth of the strain at the artificial bile concentration was observed while incubating at 37 ° C for 2 hours.

Survival Rate (%) / Oxgall (%) 0.3% 0.5% Lactobacillus plantarum DSR J1-8 118.14 100 Lactobacillus plantarum KCTC3108 51.43 32.45

As a result, as shown in Table 6, Lactobacillus plantarium DSR J1-8 is active at 0.3 and 0.5% of oxgall, especially 100% survival rate at 0.5% of oxgall. Indicated.

<1-7> Antibiotic Resistance Test

The Lactobacillus plantarium DSR J1-8 strain selected in Example <1-2> was inoculated into MRS solid medium, placed on an antibiotic-containing filter (6 mm in diameter) and incubated for 24 hours to be formed by antibiotics. The size of the inhibitory ring was measured. Smaller inhibitory rings mean more resistance to antibiotics. Table 6 below shows the degree of antibiotic resistance to Lactobacillus plantarium DSR J1-8.

Antibiotic Lactobacillus plantarium DSR J1-8 (mm) Tetracycline (30 μl) 20 Erythromycin (15 μl) 12 Ampicillin (10 μl) 18 Penicillin (10IU / IE / UI) 22 Sepharosene (30 μl) 15

As described in Table 7, the DSR3-CK10 lactic acid bacteria of the present invention has excellent antibiotic resistance, and thus its activity is maintained even when used in a formal, probiotic, feed, food additive, antibacterial, pharmaceutical composition and fermented food together with antibiotics. It can be seen that it can be usefully used.

<1-8> heat resistance test

After inoculating 1% each of the Lactobacillus plantarium DSR J1-8 strain selected in Example <1-2 into 10 ml of MRS broth, the cells were grown for 5 minutes and 15 minutes at 65 ° C. Observed.

Survival rate (%) / 65 ℃ 5 minutes 15 minutes Lactobacillus plantarum DSR J1-8 68.14 42.01 Lactobacillus plantarum KCTC3108 38.65 25.23

As a result, as shown in Table 8, Lactobacillus plantarium DSR J1-8 showed 68.14% survival rate at 65 ° C for 5 minutes.

Preparation Example 1: Preparation of Probiotic Composition

Lactobacillus plantarium DSR J1-8 lactic acid bacteria of the present invention was inoculated in a medium containing 2.0% glucose, 1.0% peptone, 1.0% yeast extract, 0.2% diphosphate, 0.05% magnesium sulfate and 0.05% cysteine at 37 ° C. Culture was aerobic for 2 days. After inoculating 10% by weight of the culture solution of each strain in a solid incubator containing skim steel, soybean meal, jade powder and molasses in a weight ratio of 3: 1: 1: 1, respectively, 45-60% by weight of water was added thereto. Was added. The probiotic composition was prepared by anaerobic solid fermentation while stirring at 40 ° C. for 3 days, and the probiotic composition thus prepared contained lactic acid bacteria of 1 × 10 ⁸ cfu / g or more.

Preparation Example 2: Preparation of Food Additive Composition

Lactobacillus plantarium DSR J1-8 lactic acid bacteria of the present invention were inoculated into a medium containing 2.0% glucose, 1.0% peptone, 1.0% yeast extract, 0.2% diphosphate and 0.05% magnesium sulfate, 0.05% cysteine, respectively, 37 Incubation was incubated for 2 days at ℃. 60% by weight of the culture solution was added to a mixture of milk powder or skim milk and starch or lactose in a 1: 1 weight ratio, which was then rapidly frozen at −70 ° C. or lower and then at −60 ° C. for 36 hours. Freeze drying to prepare a composition for food addition. At this time, the temperature of the hot plate to increase the water evaporation efficiency during lyophilization was 30 ℃, wherein the prepared food additive composition was to include the lactic acid bacteria of the present invention 1 × 10 ⁸ cfu / g or more.

Preparation Example 3: Preparation of Pharmaceutical Composition

The probiotic composition powders obtained in Preparation Examples 1 and 2 were prepared into pharmaceutical compositions by molding into tablets, pills, and capsules according to a conventional method, respectively, wherein the prepared composition had lactic acid bacteria of the present invention of 1 × 10 ⁸ cfu / g or more. It was included as.

< Manufacturing example  4: Preparation of Feed Composition>

Lactobacillus plantarium DSR3-M2 lactic acid bacteria of the present invention was inoculated in a medium containing 2.0% glucose, 1.0% peptone, 1.0% yeast extract, 0.2% diphosphate, 0.05% magnesium sulfate and 0.05% cysteine Cultured aerobic for days. The culture medium and the excipient degreasing steel of each strain were simply mixed at a weight ratio of 1: 1, dried at 40 ° C. or less, and the dried mixture was ground to prepare a feed composition. At this time, the prepared feed composition was to include the lactic acid bacteria of the present invention 1 × 10 ⁸ cfu / g or more.

Korea Microorganism Conservation Center (overseas) KCCM11141P 20101210

<110> DAESANG FNF CORPORATION <120> Plant origin lactic acid bacteria Lactobacillus plantarum DSR          J1-8 having preventing effect of metabolic syndrome and its use <130> s-101214 <160> 1 <170> KopatentIn 2.0 <210> 1 <211> 1477 <212> DNA <213> Lactobacillus plantarum <400> 1 aagtcgacga actctggtat tgattggtgc ttgcatcatg atttacattt gagtgagtgg 60 cgaactggtg agtaacacgt gggaaacctg cccagaagcg ggggataaca cctggaaaca 120 gatgctaata ccgcataaca acttggaccg catggtccga gtttgaaaga tggcttcggc 180 tatcactttt ggatggtccc gcggcgtatt agctagatgg tggggtaacg gctcaccatg 240 gcaatgatac gtagccgacc tgagagggta atcggccaca ttgggactga gacacggccc 300 aaactcctac gggaggcagc agtagggaat cttccacaat ggacgaaagt ctgatggagc 360 aacgccgcgt gagtgaagaa gggtttcggc tcgtaaaact ctgttgttaa agaagaacat 420 atctgagagt aactgttcag gtattgacgg tatttaacca gaaagccacg gctaactacg 480 tgccagcagc cgcggtaata cgtaggtggc aagcgttgtc cggatttatt gggcgtaaag 540 cgagcgcagg cggtttttta agtctgatgt gaaagccttc ggctcaaccg aagaagtgca 600 tcggaaactg ggaaacttga gtgcagaaga ggacagtgga actccatgtg tagcggtgaa 660 atgcgtagat atatggaaga acaccagtgg cgaaggcggc tgtctggtct gtaactgacg 720 ctgaggctcg aaagtatggg tagcaaacag gattagatac cctggtagtc cataccgtaa 780 acgatgaatg ctaagtgttg gagggtttcc gcccttcagt gctgcagcta acgcattaag 840 cattccgcct ggggagtacg gccgcaaggc tgaaactcaa aggaattgac gggggcccgc 900 acaagcggtg gagcatgtgg tttaattcga agctacgcga agaaccttac caggtcttga 960 catactatgc aaatctaaga gattagacgt tcccttcggg gacatggata caggtggtgc 1020 atggttgtcg tcagctcgtg tcgtgagatg ttgggttaag tcccgcaacg agcgcaaccc 1080 ttattatcag ttgccagcat taagttgggc actctggtga gactgccggt gacaaaccgg 1140 aggaaggtgg ggatgacgtc aaatcatcat gccccttatg acctgggcta cacacgtgct 1200 acaatggatg gtacaacgag ttgcgaactc gcgagagtaa gctaatctct taaagccatt 1260 ctcagttcgg attgtaggct gcaactcgcc tacatgaagt cggaatcgct agtaatcgcg 1320 gatcagcatg ccgcggtgaa tacgttcccg ggccttgtac acaccgcccg tcacaccatg 1380 agagtttgta acacccaaag tcggtggggt aaccttttag gaaccagccg cctaaggtgg 1440 gacagatgat tagggtgaag tcgtnacaag gcagatg 1477

Claims (7)

α- glucosidase and Bacillus having excellent inhibitory activity of α- amylase Lactobacillus Planta volume (Lactobacillus plantarum ) DSR J1-8 [Accession Number: KCCM11141P].
Claim 1 Lactobacillus plantarum ( Lactobacillus plantarum ) DSR J1-8 [Accession No .: KCCM11141P] or a pharmaceutical composition for treating and preventing metabolic syndrome containing a culture thereof.
A probiotic composition comprising the Lactobacillus plantarum DSR J1-8 [Accession No .: KCCM11141P] or a culture thereof.
Claim 1 Lactobacillus plantarum ( Lactobacillus plantarum ) DSR J1-8 [Accession No .: KCCM11141P] or a feed composition containing a culture thereof.
Claim 1 Lactobacillus plantarum ( Lactobacillus plantarum ) DSR J1-8 [Accession No .: KCCM11141P] or a food additive composition containing the culture thereof.
Claim 1 Lactobacillus plantarum ( Lactobacillus plantarum ) DSR J1-8 [Accession No .: KCCM11141P] or fermented food containing the culture thereof.
Claim 1 Lactobacillus plantarum (Lactobacillus plantarum) DSR J1-8 [Accession Number: KCCM11141P] or a method for producing a fermented food using a culture thereof as a starter (starter).

Images